<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="84156">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02142049</url>
  </required_header>
  <id_info>
    <org_study_id>PCYC-1124-CA</org_study_id>
    <nct_id>NCT02142049</nct_id>
  </id_info>
  <brief_title>Ibrutinib and Lenalidomide With Dose Adjusted EPOCH-R in Subjects With Relapsed/Refractory Diffuse Large B-cell Lymphoma</brief_title>
  <official_title>A Multicenter Study of Ibrutinib and Lenalidomide in Combination With DA-EPOCH-R in Subjects With Relapsed or Refractory Diffuse Large B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Pharmacyclics</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Pharmacyclics</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a Phase 1b/2, open-label, non-randomized multicenter study to assess the safety and
      efficacy of ibrutinib and lenalidomide in combination with DA-EPOCH-R in subjects with
      relapsed/refractory Diffuse Large B-cell Lymphoma (DLBCL).  This study is conducted in 2
      parts where treatment will be administered in 3-week (21-day) cycles for 6 cycles.  A
      standard 3+3 design will be employed in Part 1 to determine the maximum tolerated dose
      (MTD), which will then define the dose to be used in Part 2.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>May 2014</start_date>
  <completion_date type="Anticipated">June 2017</completion_date>
  <primary_completion_date type="Anticipated">April 2017</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Number of Dose-Limiting Toxicities as a Measure of Safety and Tolerability</measure>
    <time_frame>1 year from first patient's first  dose</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Part-1: To determine the maximum tolerated dose (MTD) of the combination of ibrutinib and lenalidomide with dose adjusted EPOCH-R</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Complete Responses (CR) and Partial Responses (PR) as a Measure of Efficacy</measure>
    <time_frame>1 year after last patient's first dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Part 2 - Overall Response rate will be defined as the proportion of subjects who achieve either a CR or a PR according to the international Working Group  Response Criteria for NHL as assessed by investigator.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Complete Responses (CR) and Partial Responses (PR) as a Measure of Efficacy</measure>
    <time_frame>1 year after first patient's first dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Part-1: Overall Response rate (ORR) will defined as the proportion of subjects who achieve either a CR or a PR according to the international Working Group  Response Criteria for NHL as assessed by investigator.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of Patients with Adverse Events as a Measure of Safety and Tolerability</measure>
    <time_frame>1 year after last patient's first dose</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Part 2: The frequency (number and percentage) of treatment-emergent adverse events will be reported.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR), Progression Free Survival (PRF) and Overall Survival (OS) as a Measure of Efficacy</measure>
    <time_frame>1 year after firs patient's last dose</time_frame>
    <safety_issue>No</safety_issue>
    <description>Part 2:  DOR will be measured from the time by which the measurement criteria are met for CR or PR until the first date by which recurrent or progressive disease is objectively documented.
PFS will be measured as time from first study drug administration to disease progression or death from any cause.
OS will be measured from the time of first study drug administration until the date of death using Kaplan-Meier methodology.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Diffuse Large B Cell Lymphoma Relapsed</condition>
  <condition>Diffuse Large B Cell Lymphoma Refractory</condition>
  <arm_group>
    <arm_group_label>Part 1: Dose Level 1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib 560 mg PO + DA-EPOCH-R</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Dose Level 2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib 560 mg (PO) +lenalidomide 15 mg (PO) + DA-EPOCH-R</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Dose Level 3</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib 560 mg (PO) +lenalidomide 20 mg (PO) + DA-EPOCH-R</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1: Dose Level 4</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib 560 mg (PO) +lenalidomide 25 mg (PO) + DA-EPOCH-R</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2: Dose Level MTD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Ibrutinib 560 mg (PO) +lenalidomide at Maximum Tolerated Dose (PO) + DA-EPOCH-R</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib, DA-EPOCH-R</intervention_name>
    <arm_group_label>Part 1: Dose Level 1</arm_group_label>
    <other_name>Etoposide, Prednisone, Doxorubicin, Cyclophsosphamide, Vincristine, Rituximab, Pegfilgrastim</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ibrutinib, Lenalidomide, DA-EPOCH-R</intervention_name>
    <arm_group_label>Part 1: Dose Level 2</arm_group_label>
    <arm_group_label>Part 1: Dose Level 3</arm_group_label>
    <arm_group_label>Part 1: Dose Level 4</arm_group_label>
    <arm_group_label>Part 2: Dose Level MTD</arm_group_label>
    <other_name>Etoposide, Prednisone, Doxorubicin, Cyclophsosphamide, Vincristine, Rituximab, Pegfilgrastim</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Major inclusion criteria:

          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤2

          -  Pathologically confirmed relapsed/refractory DLBCL

          -  Subjects must have ≥1 measurable disease site on CT scan (≥ 1.5 cm in longest
             dimension).

          -  Adequate hepatic and renal function:

               -  AST or ALT ≤2.5 x ULN

               -  Serum Creatinine ≤ 2.0 mg/dL or creatinine clearance ≥60 mL/min/1.73

               -  Bilirubin ≤1.5 x ULN

          -  Adequate hematologic function:

               -  ANC &gt;1,000 cells/mm3

               -  Platelets ≥75,000 cells/mm3

               -  Hemoglobin ≥8.0 g/dL

               -  Prothrombin time (PT) and activated partial thromboplastin time (aPTT) must be
                  ≤1.5 x the upper limit of the normal range (ULN)

          -  Must be registered into the Revlimid REMS™program and be willing to comply with the
             requirements of Revlimid REMS™.

        Major Exclusion Criteria:

          -  Known central nervous system lymphoma

          -  Any chemotherapy, external beam radiation therapy, or anti-cancer antibodies within 2
             weeks

          -  Radio- or toxin-immunoconjugates within 10 weeks

          -  Prior allogenetic stem cell (or other organ) transplant within 6 months or any
             evidence of active graft-versus-host disease or requirement for immunosuppressants
             within 28 days prior to first dose of study drug
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jutta K. Neuenburg, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>Pharmacyclics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Davina Moussa</last_name>
    <phone>855-427-8846</phone>
    <email>medinfo@pcyc.com</email>
  </overall_contact>
  <verification_date>May 2014</verification_date>
  <lastchanged_date>May 19, 2014</lastchanged_date>
  <firstreceived_date>May 12, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DLBCL</keyword>
  <keyword>ABC</keyword>
  <keyword>GCB</keyword>
  <keyword>Primary Mediastinal B-cell lymphoma</keyword>
  <keyword>Pharmacyclics</keyword>
  <keyword>Lenalidomide</keyword>
  <keyword>lymphoma</keyword>
  <keyword>Rituximab</keyword>
  <keyword>EPOCH</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>No</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Doxorubicin</mesh_term>
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Lenalidomide</mesh_term>
    <mesh_term>Etoposide</mesh_term>
    <mesh_term>Prednisone</mesh_term>
    <mesh_term>Vincristine</mesh_term>
    <mesh_term>Thalidomide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
